Phosphoric Acid

證據等級: L5

預測適應症: 10 個

Phosphoric Acid: From No Established Therapeutic Indication to Osteoarthritis (Evidence Contradicts Therapeutic Direction)

One-Sentence Summary

Phosphoric acid (DrugBank DB09394) has no established original therapeutic indication in the available data — it is not currently registered with SAHPRA and functions mainly as an excipient/acidifying agent. The TxGNN model predicts a possible association with Osteoarthritis (score 98.21%), but the supporting literature actually describes phosphate/pyrophosphate crystal deposition as a pathogenic contributor to osteoarthritis, not a therapeutic mechanism, and neither of the two identified clinical trials is actually relevant to this drug-disease pair.

Quick Overview

Item	Content
Original Indication	Not established — no SAHPRA-approved indication text available; phosphoric acid is primarily known as an excipient/acidifying agent
Predicted New Indication	Osteoarthritis
TxGNN Prediction Score	98.21%
Evidence Level	L4
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Detailed mechanism of action data for phosphoric acid is not available (flagged as a High-severity data gap). Based on the literature retrieved for this candidate, phosphoric acid itself is not described as a treatment for osteoarthritis at all. Instead, the evidence base centers on basic calcium phosphate (BCP) and calcium pyrophosphate dihydrate (CPPD) crystals, which are well-documented pathological drivers of cartilage calcification, inflammation, and joint damage in osteoarthritis.

This means the mechanistic direction implied by the literature runs opposite to what a repurposing hypothesis would require: rather than phosphate/phosphoric acid alleviating osteoarthritis, elevated phosphate-containing crystal formation is associated with worsening cartilage degradation. The TxGNN score is therefore best interpreted as reflecting a strong topical/co-occurrence association between “phosphate” and “osteoarthritis” in the knowledge graph, not a validated therapeutic mechanism. The internal repurposing rationale for this candidate explicitly flags this as a weak and potentially harmful mechanistic link.

The remaining nine predicted indications for this drug were also scored Hold, and five of them (hepatopulmonary syndrome, primitive portal vein thrombosis, idiopathic copper-associated cirrhosis, early-onset familial noncirrhotic portal hypertension, hepatoportal sclerosis) share an identical prediction score with zero supporting trials or literature — consistent with an embedding-similarity artifact rather than an independent signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07049731	N/A	Not yet recruiting	224	Protein/resistance-exercise intervention for sarcopenia; matched on keywords only, no relevance to phosphoric acid or OA treatment
NCT06921720	N/A	Not yet recruiting	65	Diagnostic phosphorus-31 spectroscopy study in phosphate diabetes; not a therapeutic trial and not related to phosphoric acid repurposing

Neither trial provides evidence for phosphoric acid as a treatment for osteoarthritis; both were flagged internally as low-relevance (“Grade C”, keyword coincidence).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39089298	2024	Review	Lancet Rheumatology	CPPD crystal deposition drives inflammatory arthritis and is strongly linked to cartilage degradation/osteoarthritis — a pathogenic, not therapeutic, role
36509917	2023	Review	Nature Reviews Rheumatology	Pathological calcification (BCP/CPP crystal formation) is a hallmark of osteoarthritis progression
16716886	2006	Review	Rheumatic Diseases Clinics of North America	Calcium crystals are common, under-recognized contributors that may cause or worsen osteoarthritis
29516278	2018	Review	Current Rheumatology Reports	BCP and CPPD crystals induce inflammation and may drive OA pathogenesis
26720903	2016	Review	Current Opinion in Rheumatology	Discusses BCP crystals as a pathogenic target in osteoarthritis, not a treatment mechanism
20425024	2010	Review	Current Rheumatology Reports	Examines association between uric acid/calcium pyrophosphate crystals and osteoarthritis onset/progression
21169842	2011	Review	Current Opinion in Rheumatology	CPPD/BCP crystals are common in osteoarthritic joint fluid; role in joint damage remains under study
34732285	2021	Review	Best Practice & Research Clinical Rheumatology	Calcium crystal-related endotypes present in ~60% of OA patients; crystals implicated in disease phenotype, not treatment
20500910	2010	Editorial/Review	Arthritis Research & Therapy	Meniscal calcification correlates with OA severity; phosphocitrate (a crystal-formation inhibitor) reduces calcification — the opposite intervention direction from phosphoric acid
38877353	2024	Preclinical/Materials study	Advanced Materials	Hydrogel scaffold for OA regeneration; contains hydroxyapatite (a calcium phosphate) as a structural material, not a discussion of phosphoric acid pharmacology

All ten publications describe phosphate-containing crystals in the context of osteoarthritis pathogenesis or diagnosis, not as a therapeutic intervention.

South Africa Market Information

Phosphoric acid currently holds no SAHPRA product registration (0 licenses recorded; market status: Not Marketed). No dosage form, brand name, or approved indication text is available for South Africa.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(No SAHPRA-specific warnings, contraindications, or drug-interaction data were retrievable for this candidate; TFDA-equivalent labeling data is flagged as a Blocking data gap pending source retrieval.)

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic evidence for this candidate points in the opposite direction from a therapeutic hypothesis — phosphate-containing crystal deposition is documented as a driver of osteoarthritis pathology rather than a treatment. Combined with the absence of any relevant clinical trial evidence, no SAHPRA registration, and missing MOA/safety data, this candidate does not meet the threshold to proceed.

To proceed, the following is needed:

Mechanism of action data for phosphoric acid (currently a High-severity data gap)
TFDA/SAHPRA-equivalent Professional Information, warnings, and contraindications (currently a Blocking data gap)
A therapeutic (not diagnostic/pathogenic) rationale specifically supporting phosphoric acid administration in osteoarthritis, ideally from a dedicated pharmacology or preclinical intervention study
Re-evaluation of the other 9 ranked predictions for this drug before considering any indication other than osteoarthritis, given 5 share an identical, likely artifactual score with zero supporting evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.